Advertisements

Diacare

Quick links to important sections

Diacare

Advertisements

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Advertisements

Overview of Diacare

Property Description
Active ingredient Glibenclamide (Glyburide)
Form Oral tablet (Solid dosage form)
Pharmacological class Antidiabetic Agent / Second-generation Sulfonylurea
General purpose Blood glucose reduction
Origin Synthetic compound

What Type of Medicine is Diacare (Glibenclamide)?

Diacare is a prescription-only medication classified as an Antidiabetic Agent used to manage the condition of high blood sugar, known as hyperglycemia. Its active component is Glibenclamide, which is also identified by the International Nonproprietary Name (INN) and the US Adopted Name (USAN) Glyburide. Glibenclamide is a synthetic compound that belongs to the sulfonylurea pharmacological class.

This compound is specifically designated as a second-generation sulfonylurea, a classification that describes its role as a highly potent oral hypoglycemic agent. This classification is clinically recognized for providing a foundational, cost-effective treatment option within the management framework for Type 2 Diabetes Mellitus. While the active ingredient is widely available under various trademarks, the Diacare brand utilizes a consistent oral tablet formulation intended for systemic use.

Composition and General Purpose of Diacare Tablets

Diacare is a single-ingredient product supplied as an oral tablet for oral administration. The compound's primary mechanism of effect is its function as an insulin secretagogue. This action stimulates the pancreatic beta-cells to release stored insulin. This mechanism promotes the natural release of the hormone required for glucose metabolism.

By increasing the concentration of circulating insulin, Diacare achieves the general therapeutic goal of correcting hyperglycemia. This systemic blood glucose reduction is essential for routine diabetic management, particularly in a scenario where a patient requires an efficacious oral agent to supplement the effects of diet and exercise. The established efficacy of Glibenclamide makes it a mainstay for achieving metabolic balance.

Advertisements

What side effects are possible with Diacare?

Possible Side Effects and Safety Information

The safety profile for Diacare (Glibenclamide) is structured around official classifications detailing adverse reactions and conditions for their occurrence. As a sulfonylurea, the most frequently documented adverse effect is hypoglycemia (low blood sugar), which is generally classified as a common event in regulatory documents.

Less frequent adverse reactions are formally grouped by affected systems, including Gastrointestinal Disorders (such as nausea and abdominal discomfort) and Skin and Subcutaneous Tissue Disorders (including pruritus and rash).

Regulatory agencies also document rare, but clinically significant, Serious Adverse Reactions. These include severe and prolonged hypoglycemia, as well as significant effects on the Blood and Lymphatic System (e.g., agranulocytosis) and Hepatobiliary Disorders (e.g., hepatitis).

Safety Considerations for Specific Populations are explicitly stated in labeling. Regulatory documents note that older adults and patients with impaired renal or hepatic function have a documented increased susceptibility to severe hypoglycemia. Furthermore, the risk of hypoglycemia is noted to be greater at the initiation of therapy or during dose adjustments.

Formal regulatory limitations state that Diacare is contraindicated for use in individuals with Type 1 Diabetes Mellitus or Diabetic Ketoacidosis. It is also restricted in patients with a known hypersensitivity to sulfonylurea drugs.

Advertisements

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory profile for Diacare (Glibenclamide) overdose centers on the primary risk of profound and protracted hypoglycemia (low blood sugar), which is the principal manifestation. This severe depletion of blood glucose can lead to serious neurological and systemic distress.


Overdose Scope

Property Official Regulatory Statement
Documented overdose presentations The manifestation is profound and protracted hypoglycemia, which can lead to severe neurological symptoms.
Physiological systems affected Primarily the Central Nervous System (CNS) (leading to seizures, confusion, coma) and cardiovascular system (rapid heartbeat).
Population-specific overdose notes Patients with severe renal or hepatic insufficiency and the elderly face an increased risk of serious, prolonged hypoglycemic reactions.
Emergency-response statements Call the Poison Control Helpline. Seek immediate medical attention for any suspected overdose.
When immediate medical help is required Immediately call emergency services if the individual has collapsed, had a seizure, has trouble breathing, or cannot be awakened.

Resulting Overdose Structure

Official overdose statements:

  • Overdose can lead to life-threatening outcomes, including coma and the potential for permanent brain damage or death if uncorrected.
  • Hypoglycemia must be treated with urgency, typically involving the administration of intravenous glucose.
  • Extended hospital monitoring for 24 hours or more is required due to the drug's prolonged action and the risk of symptom recurrence.

Connection to the overall overdose profile: Regulatory documents define the Diacare overdose profile by its central risk of profound and protracted hypoglycemia, which is explicitly linked to severe consequences like coma. This inherent risk mandates that all suspected cases trigger specific, urgent actions, including immediately contacting emergency services for severe manifestations and requiring extended hospital monitoring. The official information strictly describes these manifestations and the procedural steps for medical management.

Advertisements

Therapeutic Uses of Diacare

What Diacare Treats: Main Uses and Benefits

Diacare (Glibenclamide) is a widely used oral agent relevant in the long-term management of Type 2 Diabetes Mellitus, particularly when adequate glycemic control may not be achieved through diet and exercise alone. It provides foundational pharmacological support that helps manage metabolic balance in this chronic condition. The medication is commonly used to help with high blood sugar levels.

Therapeutic Role and Symptom Relief

The primary clinical use is to address persistent hyperglycemia, a state where blood sugar levels are consistently above therapeutic goals. Diacare is applied in clinical settings that involve unstable symptom patterns and is relevant for managing symptoms that interfere with daily comfort. The medication is commonly used to help with the core indication of Type 2 Diabetes Mellitus, and helps address symptom clusters related to high blood sugar, such as excessive thirst and frequent urination.

This oral therapy supports general well-being during symptomatic phases and may help patients cope more steadily with symptom fluctuations. By achieving successful glucose control, Diacare contributes to the benefit of blood glucose reduction required for sustained diabetes management. This supports the long-term goal of managing the risk of complications and may assist in reducing the likelihood of long-term diabetes-related damage to organs like the nerves, eyes, and kidneys.


Quick Fact: Relief for Systemic Imbalance

Diacare is relevant for managing symptoms related to systemic imbalance, specifically those stemming from poorly regulated blood glucose, and supports general well-being during symptomatic phases.

Regulatory References

  1. MedlinePlus Drug Information overview on Glyburide
Advertisements

Eligibility and Restrictions for Use

Eligibility for Diacare (Glibenclamide) Use

Diacare is officially indicated for the treatment of Type 2 Diabetes Mellitus in adults. However, its use is heavily defined by strict regulatory contraindications and population restrictions based on official government documents (FDA, EMA).

Absolute Contraindications

The medicine is contraindicated and must not be used in patients with Type 1 Diabetes Mellitus or acute conditions such as Diabetic Ketoacidosis. Use is also prohibited in patients with severe liver (hepatic) or kidney (renal) impairment, a history of Porphyria, or known hypersensitivity to Glibenclamide or related sulfonamides. Additionally, it is strictly contraindicated if the patient is taking the medicine Bosentan.

Population Restrictions

Diacare is contraindicated during pregnancy and breastfeeding. Safety and efficacy are generally not established for the general pediatric population. Use in older adults (65 years and older) requires extreme caution due to the documented increased risk of severe hypoglycemia. Patients with mild-to-moderate renal or hepatic impairment and those with conditions like G6PD deficiency require special regulatory consideration.

Advertisements

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official interaction profile for Diacare (Glibenclamide) is formally classified by regulatory authorities based on specific pharmacokinetic and pharmacodynamic mechanisms.

Formal Restrictions and Contraindicated Combinations

Co-administration of Glibenclamide is strictly contraindicated with certain medicines. This prohibition includes Bosentan, due to the documented risk of elevated liver enzymes, and in certain official documentation, Miconazole (systemic or oromucosal form), which is prohibited due to the potential for severe potentiation of the hypoglycemic effect that may result in coma.

Pharmacodynamic and Metabolic Considerations

Interactions that result in an additive blood glucose-lowering effect are documented with agents such as Nonsteroidal Anti-inflammatory Agents (NSAIDs), ACE Inhibitors, and Monoamine Oxidase Inhibitors (MAOIs). Conversely, drugs like corticosteroids, estrogens, and thiazide diuretics are noted to produce hyperglycemia and may lead to a loss of blood glucose control. Glibenclamide metabolism primarily involves CYP2C9 and CYP3A4 isoenzymes. Co-administration with strong enzyme inducers, such as Rifampin, may decrease Glibenclamide exposure.

Administration Constraints and Specific Risks

A formal timing-based rule is required for co-administration with the bile acid sequestrant Colesevelam; Glibenclamide must be administered at least 4 hours prior to Colesevelam to prevent reduced absorption. Ingestion of alcohol is documented to increase the risk of severe hypoglycemic reactions. Furthermore, the label notes that patients with severe hepatic or renal impairment face an increased potential for serious, prolonged hypoglycemia due to elevated drug levels.

Advertisements

Mechanism of Action

Targeted Blockade of Pancreatic Ion Channels

The primary action of Glibenclamide is the high-affinity binding to the Sulfonylurea Receptor 1 ( SUR1) subunit of the ATP-sensitive potassium channel ( K ATP) on the pancreatic beta-cell surface. This molecular interaction acts as a blockade, inhibiting the outward flow of potassium ions ( K^+) and initiating a critical cellular event that drives the subsequent release of insulin.

Compulsory Secretion Cascade and Systemic Effect

The K ATP channel closure causes the beta-cell membrane to depolarize, swiftly opening voltage-dependent calcium channels ( VDCC) which floods the cell with Ca^2+. This spike in intracellular calcium concentration is the final signal that forces the exocytosis of stored insulin granules, resulting in a systemic surge of insulin. The elevated insulin then promotes the clearance of glucose from the bloodstream into peripheral tissues and suppresses the liver's glucose production, leading to a reduction in the overall concentration of blood glucose.

Key Mechanistic Limitation

The mechanism requires beta-cells to have residual functional capacity, as it acts only to promote the release of stored insulin, but does not initiate insulin synthesis.

Advertisements

Dosage and Administration Information

How to Use Diacare — Official Administration Guidelines

Official instructions for Diacare, which may refer to Glibenclamide tablets or Oral Rehydration Salts (ORS) depending on the specific product label, govern the strictly defined method of use. These established parameters establish the appropriate route, quantity, frequency, and timing for administration.

Administration Scope

Entity Instruction
Route of Administration Oral route.
Dosing Schedule Glibenclamide: Initial doses for adults are typically 2.5 mg to 5 mg once daily. Maximum dosage should not exceed 20 mg daily. ORS: Volume is weight/age-dependent, often requiring administration of a specific quantity (e.g., 50–100 mL) after each loose stool for prevention in children.
Timing in Relation to Meals Glibenclamide: Must be taken with a meal, typically breakfast or the first main meal. ORS: Independent of meals; administered following a fluid-loss event.
Preparation Requirements ORS (Powder): The sachet contents must be dissolved entirely in the exact specified volume of clean drinking water to ensure correct osmolarity. The solution must not be boiled after mixing.

Procedural Rules

Official guidelines mandate that the appropriate initial dose is determined prior to use. For Glibenclamide, if a daily dose exceeds a certain limit (e.g., 10 mg), it may require division into twice-daily doses. Geriatric patients must be prescribed a conservative, adjusted initial dose. For both products, a missed dose should not be doubled; the patient should simply resume the regular schedule with the next dose. Reconstituted ORS solution must be discarded after 24 hours if refrigerated or 4 hours if stored at room temperature, as per labeling requirements.

Advertisements

Recent Clinical Evidence

Research evidence / Overview of studies


Focus of Study: The Treatment’s Effects

Research explored the effects of the treatment in relation to the inflammatory response. The research focused on measuring specific outcomes, including those related to pain measures during acute flares.


Findings in Acute Flares

In a 12-week Phase III randomized controlled trial (RCT), studies assessed whether the treatment affected primary endpoints, such as the proportion of participants achieving clinical remission. A measurable difference was observed between the treatment and placebo groups for disease activity during the study period.


Comparative Research

A network meta-analysis evaluated the treatment in comparison to the standard of care, looking at relative differences in clinical response rates. Research is ongoing to evaluate whether findings from these studies relate to long-term clinical outcomes.


Observed Tolerability

Researchers included monitoring protocols for changes in liver enzyme levels. Study findings examined how subjects tolerated the treatment. Reports from the clinical trials indicated that mild gastrointestinal upset and transient headaches were among the adverse events most frequently observed.


Research Gaps and Limitations

One study explored whether combining the treatment with an existing biological agent was associated with differences in patient-reported pain scores. Research focused on the treatment excluded elderly populations, and data regarding use in this group remains limited.

Key Studies & References

  1. Tulisokibart (Previously PRA023) for Ulcerative Colitis: Efficacy and Safety in a Phase 2 Randomized Controlled Trial (ARTEMIS-UC)
  2. RASi Therapy, Elderly Patients and the Fight Against Diabetic Kidney Disease (Subgroup Analysis/Post-hoc Data)
Advertisements

Frequently Asked Questions (FAQ)

Common questions about Diacare (FAQ)


Q: What is the main reason Diacare is prescribed?

Official labeling describes the drug's purpose as an adjunct to diet and exercise for improving glycemic control (blood sugar levels) in adults who have type 2 diabetes mellitus. The drug is intended as one component of a broader management plan that includes diet and exercise.


Q: Is Diacare a type of insulin?

No, Diacare is described as belonging to the sulfonylurea class of medications. Its mechanism of action is to stimulate the pancreas to release existing insulin into the bloodstream, but the drug itself is not a form of manufactured or human insulin.


Q: How long does the effect of one dose of Diacare usually last?

The drug is described in official documentation as having a long duration of action. This property is noted to support less frequent administration, although administration frequency is always determined by a healthcare provider.


Q: What are the most common side effects people report when taking Diacare?

Clinical data reported to regulatory bodies indicate that common reactions often include gastrointestinal issues, such as nausea, heartburn, or diarrhea, as well as headache and weight gain. Hypoglycemia (low blood sugar) is also a frequent and serious reaction noted in official warnings.


Q: Is feeling nauseous common when starting Diacare?

Nausea is a reported gastrointestinal disturbance and one of the more common reactions observed in clinical data. Regulatory summaries indicate that these disturbances may resolve as the body adjusts to the medication.


Q: Can Diacare cause weight changes?

Yes, official safety information reports that weight gain is a metabolic reaction associated with the use of this medication. This effect is a factor noted in the official drug documentation.


Q: Can I take Diacare if I am taking blood pressure medication?

Official drug information indicates that Diacare is associated with a large number of potential drug interactions. Official documentation requires that a healthcare provider review all concomitant medications, including those for blood pressure, to avoid harmful interactions.


Q: Are there any specific foods or drinks to avoid while on Diacare?

Official labeling contains specific warnings about alcohol consumption, advising that it can worsen the side effects of the medication and may rarely cause severe reactions. Patients are also advised of the necessity of adhering to a diet.


Q: Does Diacare interact with over-the-counter pain relievers?

Official drug information specifies that nonprescription products, including certain salicylate pain relievers, may have an interaction with the drug. It is important to disclose the use of all over-the-counter products to a healthcare provider.


Q: Is Diacare safe for people with kidney problems?

Official documents list renal failure or severe renal dysfunction (kidney problems) as a contraindication, which means the drug is generally not appropriate for those populations. Regulatory labeling directs that kidney function must be assessed prior to starting the medication and periodically during its use.


Q: Can elderly patients use Diacare?

Official labeling directs that renal function should be assessed more frequently for geriatric patients. However, some regulatory warnings advise that older adults should generally not take this medication because it may not be as safe or effective as certain alternative treatments.


Q: Is Diacare suitable for children?

The drug is indicated by regulatory bodies for use only in adults with type 2 diabetes mellitus. The official indication is restricted to adults with type 2 diabetes mellitus.


Q: Has Diacare been studied in long-term clinical trials?

The drug's official approval is based on clinical trial data, which includes studies designed to evaluate its effects over specified periods. Official documentation contains information about the clinical trials and the periods over which the drug was studied.


Q: What kind of evidence supports the use of Diacare?

Official documents describe that the evidence supporting the drug's approved use includes clinical trials assessing its effect on blood sugar control. This evidence is generated by studying the drug as an adjunct to diet and exercise in the target population.


Q: What are the signs of a serious reaction to Diacare?

Serious reactions reported to official bodies include severe hypoglycemia (very low blood sugar), potential liver problems, and signs of an allergic reaction such as swelling of the face, lips, or tongue, and difficulty breathing. Patients should be aware of these official warnings.


Q: What official body approved Diacare for use?

The drug is approved for use by government drug agencies, such as the U.S. Food and Drug Administration (FDA), as well as similar regulatory bodies in other countries. These bodies create the official documents that specify the approved use and conditions.


Q: Can Diacare affect my ability to drive?

Since the medication is associated with low blood sugar (hypoglycemia), which can cause symptoms like dizziness or light-headedness, caution is warranted. Patients are advised in some regulatory summaries to be aware of how the drug affects them before driving or operating machinery.


Q: Does Diacare have a warning about alcohol consumption?

Yes, official warnings advise that alcohol consumption can worsen the side effects of the medication. It may also rarely cause a severe reaction with symptoms such as flushing, headache, and nausea, which is noted in patient information.


Q: Are there any known interactions between Diacare and herbal supplements?

Official labeling directs patients to be forthcoming with their healthcare provider about all substances they are taking. This includes prescription and nonprescription medicines, vitamins, minerals, and herbal products and other supplements.


Q: Can I take Diacare while I am pregnant?

Official warnings state that the use of this drug is generally not recommended during pregnancy unless a healthcare provider determines it is clearly needed. In many cases, insulin is the treatment generally advised for maintaining blood glucose levels during pregnancy.


Q: If I have a history of heart issues, can I still take Diacare?

Official documents list severe cardiac or respiratory failure, recent myocardial infarction (heart attack), and shock as conditions that preclude use. A specific cardiovascular risk warning is also noted in some regulatory documents.


Q: What should I do if the side effects of Diacare bother me?

Official information directs patients to discuss any bothersome, persistent, or unusual side effects with their healthcare provider or pharmacist. This is consistent with the official procedure for managing bothersome reactions.


Q: Is it necessary to make dietary changes while taking Diacare?

Official patient information strongly emphasizes the importance of adhering to a diet and maintaining a program of regular physical exercise while using the medication. These lifestyle changes are considered part of the overall therapeutic management.


Q: Does Diacare have any effects on liver function?

Official warnings note that the drug is contraindicated in patients with severe hepatic insufficiency (severe liver problems). Liver function abnormalities, including isolated transaminase elevations, have been reported.


Q: Where can I find the official patient information leaflet for Diacare?

Official documentation, such as the FDA-approved labeling (like the DailyMed entry or Prescribing Information), is publicly accessible. This information can be found through official government drug databases.


Q: Is it true that Diacare can be stopped suddenly?

Regulatory documents do not contain instructions for sudden discontinuation of the medication. Any changes to the regimen, including the decision to stop using the drug, must be discussed with a healthcare provider.


Q: What are the restrictions on who can use Diacare?

Official restrictions, called contraindications, prohibit the use of Diacare in patients with type 1 diabetes, diabetic ketoacidosis, and severe dysfunction of the kidney or liver. It is also contraindicated for those with a hypersensitivity (severe allergy) to the drug.


Q: Does Diacare interact with commonly used antibiotics?

Official drug information indicates that the drug interacts with many other medications, and some of these interactions can increase or decrease blood sugar levels. For this reason, official labeling requires a thorough review of all medications, including antibiotics.


Q: What is the typical timeframe for a doctor to assess if Diacare is working?

Official patient information emphasizes the necessity of regular checks on blood sugar levels (glycaemia) and other laboratory measures. These ongoing monitoring requirements allow a healthcare provider to assess the effects of the medication over time.


Q: Why do some people need to take Diacare for a long time?

The drug is approved for the treatment of type 2 diabetes mellitus, which is a chronic (long-lasting) medical condition. This type of condition typically requires long-term therapeutic management.


Q: What are the common misunderstandings about how Diacare works?

A common point of confusion is how the drug differs from insulin. Diacare acts to stimulate the pancreas to release its existing insulin, but it does not add new insulin to the body, which is a key distinction noted in official documents.


Q: Does Diacare cause low blood sugar (hypoglycemia)?

Yes, official warnings indicate that low blood sugar (hypoglycemia) is a frequent and serious side effect reported with the use of this medication. Patients should be informed about the symptoms and official guidance for managing hypoglycemia.


Q: Is Diacare used to treat type 1 or type 2 diabetes?

Official documentation explicitly states that the drug is approved for use in adults with type 2 diabetes mellitus. Its use is specifically listed as contraindicated (should not be used) in patients with type 1 diabetes.


Q: What should I tell my doctor before starting Diacare?

Official patient information instructs individuals to inform their healthcare provider about any known allergies, all prescription and non-prescription medications they are taking, and all pre-existing health conditions, including heart, kidney, or liver disease, and pregnancy status.


Q: Is Diacare addictive?

There is no reported risk of addiction, dependence, or potential for abuse listed in the official drug information. The drug is not classified as a controlled substance in regulatory documents.


Q: What are the contraindications listed in the official documents for Diacare?

Contraindications listed in official documents include hypersensitivity, type 1 diabetes, diabetic ketoacidosis, severe renal failure, and severe hepatic failure. These are conditions that generally preclude the use of the drug.


Q: Does Diacare require any special blood tests while taking it?

Official patient information advises on the need for regular checks on blood sugar levels, known as glycaemia, to monitor the medication's effectiveness. Periodic assessment of renal (kidney) function is also advised by regulatory labeling.


Q: Are there any limitations on physical activity while taking Diacare?

Official patient information emphasizes following a program of regular physical exercise as part of the overall management plan. Regulatory labeling notes that changes in physical activity may affect blood sugar levels.


Q: Why is Diacare sometimes given as an injection/pill (whichever applies)?

Official documentation specifies the oral route of administration, meaning the drug is taken by mouth, typically as a tablet or pill. This is the factual route defined in the regulatory labeling.


Q: What is the official recommended use period for Diacare?

The drug is indicated for type 2 diabetes mellitus, a condition that typically requires chronic, long-term therapeutic management. The specific duration of use is not fixed and is based on the chronic nature of the condition.


Q: Are the initial side effects of Diacare likely to go away?

Official summaries indicate that if side effects, particularly gastrointestinal ones, are mild, they may subside within a few days or a couple of weeks as the body adjusts to the medication.


Q: Does Diacare have any known interactions with birth control pills?

Official labeling advises premenopausal females of the potential for an unintended pregnancy, which suggests that the drug may have the potential to reduce the effectiveness of some hormonal contraceptives.


Q: What is the chemical name of the active ingredient in Diacare?

The active ingredient, which belongs to the sulfonylurea class, is chemically known as glyburide (or glibenclamide). This chemical name is used in all official regulatory and drug documentation.


Q: Is Diacare prescribed for conditions other than its main use?

The only conditions the drug is officially indicated to treat are those listed on the FDA-approved labeling, specifically type 2 diabetes mellitus. Regulatory documents do not address or recommend use for other conditions.

Advertisements

How should Diacare be stored and disposed of?

Official Storage and Disposal Requirements

Diacare (based on regulatory guidance for injectable diabetes medication) requires strict adherence to labeled storage conditions to maintain its effectiveness. Unopened medication must be stored in a refrigerator, typically between 2 C to 8 C (36 F to 46 F). Do not freeze the product.

Once the product is in use (opened), it can be stored at a controlled room temperature, generally not exceeding 30 C (86 F), for a specific, time-limited period, such as 28 to 42 days. The product must be protected from direct light and excessive heat, and handled without excessive shaking.

For disposal, all used needles and syringes must be placed in a designated, puncture-resistant sharps disposal container and managed according to local and national hazardous waste regulations. Unused or expired medication should be disposed of under proper inventory control and should not be flushed down the toilet or poured down a drain.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Diacare found in:

A-Z Index: